X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 20.0 33.7 59.2% View Chart
P/BV x 3.5 2.9 118.9% View Chart
Dividend Yield % 0.3 0.6 52.1%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
CIPLA
Mar-18
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs930663 140.3%   
Low Rs517479 108.0%   
Sales per share (Unadj.) Rs322.6189.0 170.7%  
Earnings per share (Unadj.) Rs28.517.6 161.9%  
Cash flow per share (Unadj.) Rs39.234.0 115.2%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.30.5 52.6%  
Book value per share (Unadj.) Rs183.0176.7 103.5%  
Shares outstanding (eoy) m282.17805.12 35.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.23.0 74.3%   
Avg P/E ratio x25.432.5 78.3%  
P/CF ratio (eoy) x18.516.8 110.0%  
Price / Book Value ratio x4.03.2 122.4%  
Dividend payout %7.017.1 41.2%   
Avg Mkt Cap Rs m204,206459,724 44.4%   
No. of employees `00013.723.6 58.1%   
Total wages/salary Rs m18,71826,901 69.6%   
Avg. sales/employee Rs Th6,636.86,446.1 103.0%   
Avg. wages/employee Rs Th1,364.71,139.4 119.8%   
Avg. net profit/employee Rs Th586.1600.0 97.7%   
INCOME DATA
Net Sales Rs m91,031152,193 59.8%  
Other income Rs m9143,577 25.6%   
Total revenues Rs m91,945155,769 59.0%   
Gross profit Rs m16,15428,264 57.2%  
Depreciation Rs m3,01913,228 22.8%   
Interest Rs m2,8561,142 250.0%   
Profit before tax Rs m11,19317,470 64.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m3,1552,501 126.1%   
Profit after tax Rs m8,03914,166 56.7%  
Gross profit margin %17.718.6 95.6%  
Effective tax rate %28.214.3 196.9%   
Net profit margin %8.89.3 94.9%  
BALANCE SHEET DATA
Current assets Rs m69,887108,141 64.6%   
Current liabilities Rs m32,87938,322 85.8%   
Net working cap to sales %40.745.9 88.6%  
Current ratio x2.12.8 75.3%  
Inventory Days Days8197 83.9%  
Debtors Days Days9374 125.7%  
Net fixed assets Rs m28,892109,411 26.4%   
Share capital Rs m2821,610 17.5%   
"Free" reserves Rs m51,353140,682 36.5%   
Net worth Rs m51,635142,292 36.3%   
Long term debt Rs m41,41836,621 113.1%   
Total assets Rs m125,954228,606 55.1%  
Interest coverage x4.916.3 30.2%   
Debt to equity ratio x0.80.3 311.7%  
Sales to assets ratio x0.70.7 108.6%   
Return on assets %8.66.7 129.2%  
Return on equity %15.610.0 156.4%  
Return on capital %15.110.0 151.7%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31751,691 70.3%   
Fx outflow Rs m9,72021,033 46.2%   
Net fx Rs m26,59830,658 86.8%   
CASH FLOW
From Operations Rs m16,48114,628 112.7%  
From Investments Rs m-10,133-8,540 118.7%  
From Financial Activity Rs m-4,685-3,855 121.5%  
Net Cashflow Rs m1,7702,431 72.8%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 11, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - UNICHEM LAB COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS